Fertility, gonadal and sexual function in survivors of testicular cancer by Huddart, R A et al.
Fertility, gonadal and sexual function in survivors of testicular
cancer
RA Huddart*,1, A Norman
2, C Moynihan
1, A Horwich
1, C Parker
1, E Nicholls
1 and DP Dearnaley
1
1Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey
SM2 5PT, UK;
2Department of Computing and Information, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road,
Sutton, Surrey SM2 5PT, UK
Modern treatments cure most testicular cancer patients, so an important goal is to minimise toxicity. Fertility and sexual functioning
are key issues for patients. We have evaluated these outcomes in a cross-sectional study of long-term survivors of testicular cancer. In
total, 680 patients treated between 1982 and 1992 completed the EORTC Qly-C-30(qc30) questionnaire, the associated testicular
cancer specific module and a general health and fertility questionnaire. Patients have been subdivided according to treatment
received: orchidectomy either alone (surveillance, S n¼169), with chemotherapy (C, n¼272), radiotherapy (R, n¼158), or both
chemotherapy and radiotherapy (C/RT n¼81). In the surveillance group, 6% of patients had an elevated LH, 41% an elevated FSH
and 11% a low (o10nmoll
 1) testosterone. Hormonal function deteriorated with additional treatment, but the effect in general was
small. Low testosterone was more common in the C/RT group (37% P¼0.006), FSH abnormalities were more common after
chemotherapy (C 49%, C/RT 71% both Po0.005) and LH abnormalities after radiotherapy (11% Po0.01) and chemotherapy (10%,
Po0.001). Baseline hormone data were available for 367 patients. After treatment, compared to baseline, patients receiving
chemotherapy had significantly greater elevations of FSH (median rise of 6 (IQR 3–9.25) iul
 1 compared to 3 (IQR 1–5) iul
 1 for S;
Po0.001) and a fall (compared to a rise in the surveillance group) in median testosterone levels ( 2 (IQR  8.0 to  1.5) vs 1.0. (IQR
 4.0–4.0) Po0.001). Patients with low testosterone (but not elevated FSH) had lower quality of life scores related to sexual
functioning on the testicular cancer specific module and lower physical, social and role functioning on the EORTC Qly C-30. Patients
with a low testosterone also had higher body mass index and blood pressure. Treatment was associated with reduction in sexual
activity and patients receiving chemotherapy had more concerns about fathering children. In total, 207 (30%) patients reported
attempting conception of whom 159 (77%) were successful and a further 10 patients were successful after infertility treatment with
an overall success rate of 82%. There was a lower overall success rate after chemotherapy (C 71%; CRT 67% compared to S 85%
(P¼0.028)). Elevated FSH levels were associated with reduced fertility (normal FSH 91% vs elevated 68% Po0.001). In summary,
gonadal dysfunction is common in patients with a history of testicular cancer even when managed by orchidectomy alone. Treatment
with chemotherapy in particular can result in additional impairment. Gonadal dysfunction reduces quality of life and has an adverse
effect on patient health. Most patients retain their fertility, but the risk of infertility is likely to be increased by chemotherapy. Screening
for gonadal dysfunction should be considered in the follow-up of testicular cancer survivors.
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Testicular cancer is the most common cancer of young men in
their 20s and 30s. Since the advent of effective multiagent
cisplatinum-based chemotherapy, the majority of patients are
cured. This disease occurs during the peak period of reproductive
life and at a key time for career and family. As cured testicular
patients have a long life expectancy, minimising effects on long-
term health and quality of life are important goals. To understand
the long-term effects of testicular cancer treatment on fertility,
gonadal and sexual function we have surveyed survivors of
testicular cancer more than 5 years after diagnosis. These aspects
have been studied as part of a broad ranging cross-sectional study
of patients treated for testicular cancer between 1982 and 1992 at
our institution.
PATIENTS AND METHODS
Details of the study methodology have been previously reported
(Huddart et al, 2003). In brief, all UK resident male patients
registered between 1982 and 1992 at The Royal Marsden NHS
Trust with a diagnosis of germ cell tumour, who had completed
cancer treatment more than 5 years previously, were eligible for
entry into this study. A total of 1603 patients were registered
during this time period. Of these, 200 were considered ineligible
(by virtue of overseas residence (163), female sex (3) or recent
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streatment or additional cancer diagnosis (34)) and 203 had died
leaving 1200 patients eligible for recruitment. Of these, 739
patients were recruited with 59 patients declining consent to the
study and 402 patients being either lost to follow-up or not seen in
the clinic during time-frame of the study (October 1997 and
February 1999). The baseline characteristics and treatment
received by recruited patients is similar to that of the eligible
cohort (Table 1 and see Huddart et al, 2003).
Patients gave written consent to the study and completed a
general health questionnaire and quality of life form (EORTC
QLYC-30) along with the testicular cancer module, which included
questions on sexual activity. The health questionnaire asked
specific questions regarding fertility following treatment. A clinical
review was undertaken and blood was drawn for a range of tests
including LH, FSH and testosterone. All biochemical results and
blood pressure were notified to the patient’s local doctor. Prior to
1990, postorchidectomy, preradiotherapy/chemotherapy gonadal
hormone levels were routinely collected. These results form the
basis for longitudinal hormone comparisons with matched
individual data available on 367 patients. Semen analysis was not
performed in this study.
The study was undertaken according to a protocol agreed by the
local research ethics committee (Ethics No. 1387). This report will
focus on the hormonal function and fertility aspects of the study.
Statistical methods
Patients registered at the Royal Marsden NHS Trust with a
diagnosis of testicular cancer, in the time period 1982–1992, were
prospectively identified on the Bob Champion Unit research
database prior to initiation of the study (second opinions on
management were not included). Eligible patients according to
predefined criteria booked in the long-term follow-up clinic in the
period from October 1997 to February 1999 were identified and
contacted as described in the Materials and methods section.
Information collected at the clinic visit including blood tests and
questionnaire information was prospectively entered onto the Bob
Champion Unit research database. For all patients with data
collected in the clinic, descriptive analysis was performed on all
variables and comparisons were made between the four treatment
groups. Categorical data were examined using the w
2 test and
continuous variables were compared using the Mann–Whitney
nonparametric test unless otherwise stated. Paired data were
assessed by the Mann–Whitney or the Wilcoxson tests. Results
from the core EORTC Qly C-30 questionaires were analysed
according to the standard methods (Fayers et al, 2001). Substitu-
tions for missing results were not performed, and incomplete
domains were not analysed. The testicular module allowed patients
to choose whether or not to answer questions on sexuality. This
option was exercised by a variable number of patients according to
the question (60–130 per question). Thus, no overall rating is given
for this section, but results analysed on a question by question basis.
RESULTS
Patient characteristics
Characteristics of the patient cohort are as previously described
(Huddart et al, 2003) and are summarised in Tables 1 and 2. Of the
739 patients who gave their consent to the the study, 59 have been
excluded from this analysis as they had either a second
orchidectomy (synchronous n¼3, metachronous n¼47) or an
absent contralateral testis (n¼9). Of the remaining cohort of 680,
questionnaires were completed by 640. Of these patients, 367
treated prior to 1990 had pretreatment postorchidectomy (base-
line) hormone levels. The surveillance group received no treatment
except for orchidectomy (n¼169, 114 with baseline data). This
group acts as a reference for derivation of treatment-related effects.
The other groups consisted of 158 (61 with baseline data) patients
treated by radiotherapy alone, 272 (146 with baseline data) patients
who had treatment with chemotherapy alone and 81 (46 with
baseline data) patients who had received both chemotherapy and
radiotherapy at some stage of their treatment.
The majority of patients in the radiotherapy group received
dogleg radiotherapy to a dose of 30Gy for stage I seminoma. The
majority of patients treated by chemotherapy received cisplatin-
based chemotherapy, most commonly with the BEP regimen
(44%), but a third of patients received a carboplatin-based regimen
(carboplatin alone or carboplatin/etoposide/bleomycin). Patients
in the combined group most commonly (70%) received radio-
therapy after chemotherapy for advanced disease, although
approximately 10% of these patients had received single agent
carboplatin and radiotherapy for stage IIa/b seminoma (Table 2).
Fertility
Only 207 (30%) patients reported attempting conception after
treatment. In the surveillance group, 34% of patients conceived
children following diagnosis compared to 18–21% of patients in
groups receiving treatment (Table 3). Some caution has to be used
Table 1 Characteristics of patients in long-term follow-up study
No. of patients
assessed Chemotherapy
Chemotherapy/
radiotherapy Radiotherapy Surveillance Total
Patients in cohort
All patients treated
1982–1992
660 271 331 341 1603
Full data available 292 90 175 182 739
Patients eligible for
fertility study
$
272 81 158 169 680
Number of deaths
Dead of TT 67 74 0
a 0
a 141
Dead of other causes 24 10 16 12 62
Age at presentation
(median and range)
1603 28 (10–62) 32 (15–68) 35 (19–82) 31 (13–82) 31.71 (10–82)
Age at follow-up
(median and range)
739 41 (23–72) 47 (30–69) 47 (29–78) 45 (27–76) 44 (23–78)
Median follow-up (years) 1603 9.7 years (0–19.8) 11.9 years (0.2–19.9) 9.48 years (0.1–20.3) 11.4 years (0–19.9) 10.2 (0–20.3)
aAll patients relapsing after radiotherapy or surveillance will have received chemotherapy so will be included in one of the other groups and hence there are no deaths of disease
in these groups.
$To be eligible for this study, patients had to have one or more remaining testicles.
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sin interpreting these data as they reflect both the level of fertility
and how commonly patients in each group attempted conception.
Only 22% of the radiotherapy group, who have a higher median
age than the other groups, attempted conception compared to 39%
in the surveillance group.
When attempted, the success rate was high with 159 (77%)
reporting success without intervention and a further 10 patients
(5%) were successful after infertility treatment (four by artificial
insemination and six by in vitro fertilisation). There was a trend to
lower success rate in groups receiving chemotherapy (S (85% success
without fertility treatment), any chemotherapy 70% P¼0.028).
FSH
There was evidence of significant elevations of FSH in all groups
(Table 4). In total, 42% of surveillance patients had an FSH above
the normal range (410iul
 1). Elevated FSH was found more
frequently in all groups of patients receiving treatment, with the
combination treatment group (70% elevated) being the most
frequently affected (Table 4).
Patients with elevated FSH were significantly less likely to have
conceived children after their treatment. In total, 55 of 311 (17.7%)
patients with elevated FSH (68% of the 81 who tried to conceive)
had children compared to 101 of 329 (30.7%) with normal FSH
levels (91% of 111 who tried to conceive) (Po0.001). In contrast,
there was no difference in the conception rate of patients with
abnormal compared to normal testosterone levels.
LH/testosterone
This survey revealed significant gonadal dysfunction in all patient
groups. These changes are summarised in Table 4. In the
surveillance group, 11% of patients had a subnormal level of
testosterone (o10nmoll
 1) and 6% had evidence of a raised LH
(412iul
 1). Treatment with chemotherapy or radiotherapy alone
resulted in mean levels of LH higher than after orchidectomy alone
(Po0.01), but this did not affect testosterone levels. Patients who
received both chemotherapy and radiotherapy, however, did have
significantly greater risk of low testosterone levels (P¼0.006).
Hypogonadism was common in this group with 38% of patients
having either subnormal testosterone or testosterone replacement.
Comparison of hormonal function at baseline and at
follow-up
Data at baseline and follow-up are available on 367 patients. These
results are shown in Table 5. The median levels of their hormones
at follow-up of this group are similar to the levels for the group as
a whole (Table 4). At baseline, patients receiving chemotherapy
had significantly lower FSH levels and higher LH and testosterone
levels. There was a weak correlation between the level of HCG and
LH levels, suggesting a degree of interaction between the two
factors (R¼0.266, Po0.001). There was also a similarly weak
correlation between age and FSH levels (R¼0.264, Po0.0001), and
testosterone (R¼0.247, Po0.0001), but not for LH. However,
these correlations only partially explain this difference.
Table 2 Disease and treatment characteristics of patients treated at The Royal Marsden Hospital between 1982 and 1992 entered into this study
Chemotherapy Chemotherapy/radiotherapy Radiotherapy Surveillance Overall
N 272 81 158 169 680
Histology
Seminoma 32 46 157 57 292
NSGCT 240 35 1 112 388
aChemotherapy regimes
Platinum 120 19 139
BEP
BOP 35 3 38
PVB 12 14 26
Other platinum regimes 13 3 16
Carboplatin
Only 18 33 51
JEB 74 7 87
Other 0 2 2
Reason for radiotherapy
Elective after chemotherapy 61 — 61
Stage I seminoma 4 130 134
Stage II seminoma 12 27 39
Stage I/II NSGCT 4 1 5
NSGCT, nonseminomatous germ cell tumour.
aB, Bleomycin; E, Etoposide; P, Cisplatinum; J, Carboplatin; V, vinblastine; O, vincristine.
Table 3 Summary of the ability to conceive after treatment for testicular cancer
Chemotherapy Chemotherapy/radiotherapy Radiotherapy Surveillance Total
N 272 81 158 169 680
Tried to conceive 83 (31%) 24 (30%) 34 (22%) 66 (39%) 207 (30%)
Successful (no infertility treatment) 59 (71%) 16 (67%) 28 (82%) 56 (85%) 159 (77%)
Successful with infertility treatment 3 4 1 2 10
Unsuccessful 21 4 5 8 38
Overall success rate
a 75% 83% 85% 88% 82%
aSuccessful with or without infertility treatment out of all who tried to conceive.
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sOn follow–up, FSH levels tend to be higher than at baseline.
Treatment with chemotherapy (alone or in combination with
radiotherapy) resulted in both higher FSH levels (despite lower
baseline levels) and greater rises in FSH over time.
Patients on surveillance had 1.0nmoll
 1 rise in median
testosterone compared to baseline levels on follow–up, but after
chemotherapy there was a fall in testosterone ( 2nmoll
 1)
(Po0.01). As baseline levels for chemotherapy patients were
initially higher, the end result was of similar testosterone levels at
follow-up with or without chemotherapy except in the combina-
tion treatment group (P¼0.02).
Sexuality and treatment
We have investigated the long-term effects of treatment on
sexuality by using the testicular module of the EORTC Qly C 30.
This consists of six questions directed at sexual function and
sexual satisfaction and two additional questions about effects on
masculinity and concerns about fathering children. The results of
these questions have been analysed by comparing the overall
scores of patient groups and by the number of patients reporting
significant effect (‘quite a bit’ or ‘very much’). A proportion of
patients (between 60 and 165 of 680 patients) did not answer these
questions with no significant bias by treatment group. Overall
sexual function seemed to be satisfactory with 83% of patients
expressing satisfaction in their sexual relationships with their
partner with no differences between treatment groups (Figure 1).
Compared to surveillance there was a tendency for treated groups
to have less sexual activity and less interest in sex. This was only
statistically significant for CRT and less interest in sex (P¼0.01)
and borderline significant for CRT and RT and less sexual activity
(both P¼0.051). Additionally, radiotherapy treatment was asso-
ciated with reduced sexual enjoyment (RT vs S P¼0.05).
Compared to surveillance patients, patients treated by chemother-
apy had more worries about fathering children (P¼0.009).
Effects of hormonal function on patients’ quality of life
Although 72% of patients with low testosterone continued to
report that sex was satisfying, there was evidence of significant
morbidity in all six domains of the testicular quality of life module
that relate to sexual activity. These results are summarised in
Table 6. In addition to effects on sexuality, men with a low
testosterone had evidence of more general impairment in quality
Table 4 Hormonal levels in patients on long-term follow-up by treatment group
Chemotherapy Chemotherapy radiotherapy Radiotherapy Surveillance
Testosterone
Mean 14.8 12.8 14 14.6
Median 14 12** 14 14%
Low 13% 34% 15% 11%
Testosterone replacement 0% 4% 0.60% 0
FSH
Mean 14.6 21.5 13.8 11.9
Median 10* 19*** 10 9
Raised 49% 71.00% 45% 41%
LH
Mean 7.5 9.8 7.2 5.8
Median 6*** 8*** 6** 5
Raised 10% 22% 11% 6%
Raised or low levels indicate above or below the normal ranges for assay (testosterone 10–30ngml
 1, FSH 1–10iul
 1,L H1–1 2i ul
 1). Asterisks indicate significant difference
to surveillance patients (*Po0.05, **Po0.01, ***Po0.001).
Table 5 Hormonal levels in patients with paired baseline and follow-up hormone profiles
Chemotherapy Chemotherapy/radiotherapy Radiotherapy Surveillance Overall
N 146 46 61 114 367
FSH (iu1
 1)
Baseline 4* (2–8) 8 (3.75–19) 7 (5–10) 7 (4–10) 6
Follow-up 10* (8–18) 19* (9.25–31.75) 10 (7–15.25) 9 (6–13.25) 10
Difference 6* (3–9.25) 11* (4–19) 3 (1–7) 3 (1–5) 4
LH (iu1
 1)
Baseline 11* (6–38.75) 9* (6–17.25) 8 (5–10) 6 (4–10) 8
Follow-up 6* (4–9) 8* (5–12) 6* (4–8) 5 (4–7) 6
Difference –4* ( 28.5 to  1)  1(  5.5–4.5)  1(  3–1.0)  1(  4–1.0)  2
Testosterone (nmoll
 1)
Baseline 17* (13–21) 13 (10–16) 13 (11–16) 13 (11–17) 15
Follow-up 14 (11–17.5) 12 (9–17) 14 (10–16) 14 (11–17) 14
Difference  2* ( 8–1.5)  2(  5.25–4.0)  1(  4–2.0) 1 ( 4–4.0)  1
All baseline levels are postorchidectomy and prechemotherapy or radiotherapy. Follow-up samples are a minimum of 5 years post-treatment. The presented data are not
normally distributed, so presented values in the table are median (interquartile range). Normal ranges as presented in Table 4. *Statistically different to surveillance (Po0.01).
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sof life. Low testosterone levels were associated with lower quality of
life scores for physical (Po0.001), social (P¼0.002) and role
functioning (P¼0.003) and a trend to impaired global QoL
(P¼0.05) (Figure 2). Low testosterone was also associated with a
marked increase in dyspnoea (mean score 14.3 (95% CI 9.4–19.3)
compared to 6.4 (CI 5.0–7.8) Po0.001) and lesser increases in the
complaint of pain (P¼0.048), sleep disturbance (P¼0.039),
constipation (P¼0.03) and nausea (P¼0.031).
Patients with elevated LH levels reported more worries
regarding fathering a child (P¼0.001), less sexual activity
(P¼0.005), but otherwise there were no significant associa-
tions with reduced sexual quality of life. Elevated FSH levels were
not associated with impaired sexual quality of life apart from
feelings of less masculinity, which is of borderline significance
(P¼0.018).
As well as quality of life effects, we have previously recognised
that low testosterone is associated with a higher body mass
Index compared to those with normal testosterone levels (median
BMI of 28.6 compared to 25.7kgm
 2; Po0.001) (Huddart and
Norman, 2003). Low testosterone is also associated with higher
systolic (median 140 compared to 130 Po0.004) and diastolic
blood pressure (median 90 compared to mean 85 Po0.016)
(Figure 3).
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Figure 1 Effect of treatment level on sexual quality of life. Mean scores represent the average score for the question. Each question is scored on a 4-point
scale from 1 (none) to 4 (very much). Results statistically significant different (Pp0.05) from surveillance are indicated by *.
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Figure 2 Effect of hormone levels on quality of life. Mean scores represent the average score for the question. Each question is scored on a 4-point scale
from 1 (none) to 4 (very much). Results statistically significant different (Pp0.05) from surveillance are indicated by *.
Table 6 Effect of testosterone on sexual quality of life
Testosterone level
Category n Normal Low
Worried about fathering child 622 22/502 (4%) 11/95 (12%) P¼0.01
Less interested in sex 600 45/486 (9%) 22/92 (24%) Po0.001
Less sexually active 599 97/484 (20%) 33/93 (35%) P¼0.001
Sex less enjoyable 550 25/449 (6%) 14/81 (17%) Po0.001
Difficulty getting erection 553 28/481 (6%) 12/81 (14%) P¼0.008
Sex has been satisfying 515 358/420 (85%) 53/74 (72%) P¼0.004
Feeling less masculine 624 19/504 (4%) 9/95 (9%) P¼0.03
Data are presented as the proportion of patients reporting ‘quite a bit’ or ‘very much’
for the question. Comparisons between groups undertaken by Fishers exact test.
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sDISCUSSION
The development of testicular cancers is associated with other
testicular abnormalities such as testicular maldescent, testicular
atrophy and subfertility (United Kingdom Testicular Cancer Study
Group, 1994; Moller and Skakkebaek, 1999; Fossa and Kravdal, 2000).
Preorchidectomy sperm counts and LH levels are lower and FSH
levels higher than age-matched normal controls and patients
presenting with lymphoma in a Danish study (Petersen et al, 1999).
Initial management in most patients is with orchidectomy, so it could
be anticipated there would be evidence of gonadal dysfunction in a
significant proportion of patients. In this study we have confirmed
that indeed gonadal dysfunction is common after treatment for
testicular cancer and it is of some concern that we note that over 13%
of our patients have either a subnormal testosterone or are on
testosterone replacement therapy. There are only limited published
data on the hormonal function of patients after orchidectomy alone
(summarised in Table 7). The two largest previous studies reported
findings similar to ours with subnormal testosterone in 5% (Gerl et al,
2001) and 16% (Aass et al, 1991) of patients.
The deleterious effects of low testosterone are well recognised in
a number of patient groups including patients receiving hormone
therapy for prostate cancer (Bates et al, 1996; Simon et al, 1997;
Smith et al, 2001). Our results clearly show a similar impact on the
quality of life of testicular cancer patients with low testosterone. We
have already demonstrated in a previous report that low
testosterone is associated with increases in body mass index
(Huddart and Norman, 2003) and that elevated LH and FSH are
associated on univariate (though not multivariate) analysis with an
increased risk of cardiac events (Huddart et al, 2003). Additionally,
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Figure 3 Relationship between systolic (A) and diastolic (B) blood pressure and testosterone status. Lowered refers to a testosterone level below the
normal range (see text for details).
Table 7 Overview of data on hormonal function of long term survivors of testicular cancer
Proportion of patients with abnormal hormone levels
Orchidectomy only Orchidectomy plus chemotherapy
Publication n Testosterone LH FSH n Testosterone (%) LH (%) FSH (%)
Drasga et al (1983) — — — — 28 25 43 53
Leitner et al (1986) — — — — 22 0 86 63*
Kreuser et al (1989) — — — — 44 0 2 10
Stuart et al (1990) 11 0 45% 45% 27 0 67 75
Hansen et al (1990) 9 0 11% NS 22 13* 59* 86
Aass et al (1991) 36 16% 6% 24% 42 14 37 37*
Berger et al (1996) — — — — 63 10 24 63
Brennemann et al (1997) 11 NS NS 27% 232 5.2 13.4 64
Gerl et al (2001) 58 5% 12% 53% 117 11 19 53
Jacobsen et al (2001) 60 NS NS 17% — — — —
Strumberger et al (2001) — — — — 32 12 47 75
Huddart et al (this series) 179 13% 8.7% 43% 290 15 13* 50*
*Significantly different from result with no chemotherapy. NS¼not stated.
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sin this study we have shown that patients with low testosterone
have higher average systolic and diastolic blood pressure. As would
be anticipated, we have shown that a low testosterone has a
significant effect on the quality of sexual experience, although it is
interesting to observe that up to three quarters of men with low
testosterone report satisfaction with their sexual life. We do not
have direct data on how much this represents satisfaction with their
relationships rather than sexual activity per se or whether lower
libido allows satisfaction with lower activity. A similar effect on
sexual activity of mild leydig cell insufficiency has also been
reported in men after treatment for haematological malignancy
(Howell et al, 2000). Low testosterone was also associated with a
reduction in more general aspects on quality of life including
physical functioning, role and social effects. The difference between
patients with normal and low testosterone in these domains is in
the order of 5–6%. The clinical significance of these differences is
open to interpretation. It is commonly considered that a difference
of 10% on these scales is an important difference for an individual
patient. In these averaged results, which contain patients with lesser
and greater differences, we believe these statistically significant
results represent important and clinically relevant findings. We can
only speculate on whether this is a direct effect or secondary to
effects on sexual functioning and masculinity. Fatigue was not
significantly worse in these patients with a low testosterone, a
finding similar to that of Howell et al (2000) in haematological
patients, but, perhaps surprisingly, patients with a low testosterone
reported high levels of dyspnoea. The reason for this is unclear.
In addition to low testosterone, we have also noted elevations of
LH and FSH in a significant proportion of our patients, a finding
similar to other smaller studies (Hansen et al, 1990; Stuart et al,
1990; Gerl et al, 2001). A recent large Norwegian study found
similar abnormalities in LH, which were significantly elevated
compared to normal controls even in those treated by orchidect-
omy alone (Nord et al, 2003).
In common with other reports we have observed increases in LH
and FSH levels following chemotherapy (Table 4). However, the
level of gonadal dysfunction due to the treatment effect seems to be
on average less than that reported in previous studies (Table 7).
There may be a number of reasons for this. A number of studies
have shown that the gonadal dysfunction is greatest immediately
after chemotherapy (Stuart et al, 1990; Brennemann et al, 1997,
1998). For instance, Brennemann et al (1997) in a cross-sectional
study showed a higher rate of elevated LH and FSH levels in the
first year compared to the number measured after 8 years of
follow-up (LH 32% vs 3.6%, FSH 89% vs 64%). As the median
follow-up of our cohort is over 10 years, this lower level of
dysfunction may reflect that a degree of recovery of the pituitary–
gonadal axis has occurred with time.
However, this may not be the complete explanation as Gerl et al
(2001) could detect no difference in LH, FSH and testosterone
levels in patients measured between 24 and 60 months and over 60
months. Our Longitudinal data suggest that for surveillance
patients there is little change or even a small rise in levels with
follow-up. Seeing a rise in median levels would be unexpected as
testosterone levels usually decline with age, but could be explained
by temporary reduction in testosterone at diagnosis due to tumour
development or the effect of recent orchidectomy, which recovers
with follow-up. This contrasts with chemotherapy-treated patients,
who have higher baseline levels of testosterone and LH and lower
FSH levels at diagnosis. This may be due to an interaction between
LH and HCG levels and their younger median age (for FSH and
testosterone). On follow-up, on average, both testosterone and LH
levels fell after treatment. For most patients this fall is modest, but
25% of patients had a greater than 8ngml
 1 fall in testosterone. As
there is difference in baseline values between those who received
chemotherapy and patients managed by surveillance, the net effect
is to achieve levels similar to that seen in patients treated by
orchidectomy alone. The data on testosterone could suggest an
effect of chemotherapy on testosterone levels, but could be equally
interpreted as being due to a differential effect on baseline results
due to disease or age-related factors.
Our study could also differ from previous reports due to
differences in the chemotherapy utilised. Previous studies have
suggested greater dysfunction in patients receiving higher doses of
cisplatin chemotherapy (Berger et al, 1996; Bokemeyer et al, 1996;
Gerl et al, 1997), vinblastine (Berger et al, 1996; Bokemeyer et al,
1996) and ifosphamide (Brennemann et al, 1997). The majority of
our chemotherapy-treated patients received etoposide rather than
ifosphamide- or vinblastine-based chemotherapy and additionally
almost a third of our patients received carboplatin rather than
cisplatin. This view is supported by the greater degree of hormonal
dysfunction seen in our intensively treated combination treatment
group, many of whom had received intensive salvage treatment.
A number of studies have reported the effects of direct testicular
irradiation when applied for carcinoma in situ, but there is little
long-term data on the effect of scattered irradiation from an
abdominal field (Fossa et al, 1993; Brennemann et al, 1997; Petersen
et al, 2002). Despite statistically significant higher LH levels, our
results, like the previous studies, suggest that dogleg radiotherapy
probably results in minimal long-term hormonal effects.
In this study we have not undertaken analysis of spermatogenesis,
but a number of studies (Fossa ˚ et al, 1985; Kreuser et al, 1989; Aass
et al, 1991; Brennemann et al,1 9 9 8 ;J a c o b s e net al, 2001) have
emphasised the close correlation between FSH levels and sperm
counts. On this basis the elevated level of FSH would suggest that there
is a significant long-term impairment of spermatogenesis. In support
of this view we were able to observe a clear relationship between FSH
elevation and the ability to conceive. However, this is not a clearcut
relationship as many patients with elevated FSH do still remain fertile.
Our results have shown that though success is less likely with a raised
FSH, over 2/3 of such patients were still able to conceive.
The long-term effect of chemotherapy on spermatogenesis at our
institution has been previously reported (Lampe et al, 1995). In this
study we noted that 80% of patients who were normospermic
before treatment had spermatogenesis by 5 years and the chance of
recovery was better if carboplatin and less than four cycles were
used. Similar results have been reported by other authors (Drasga
et al, 1983; Fossa et al, 1993; Petersen et al, 1994). For instance,
Drasga et al (1983) found that 46% of patients had normal sperm
counts 2–3 years after treatment despite only 6.6% having normal
spermatogenesis pretreatment. The results of our previous study
are reflected in the gratifying success rate of patients attempting to
have children despite the substantial evidence of gonadal dysfunc-
tion. Although only 25% of patients had successful conception, this
represented 77% of the 207 patients who reported attempting
conception. This rose to 82% with the aid of infertility treatment.
Radiotherapy treatment had no detrimental effect on this success
rate, although only a small proportion of patients attempted
conception. This is in keeping with the observations in the MRC-
randomised trial of dogleg vs para-aortic radiotherapy that by 3
years 92% of patients treated by dogleg radiotherapy have re-
attained sperm counts of 10millionml
 1 or greater.
Success rate appeared to be lower after chemotherapy, in line
with the elevations in FSH that we observed. Most of this is likely
to be a direct effect on germ cell function, but there may also be a
contribution from dry ejaculation which was reported as ‘quite a
bit’ or ‘very much’ in 3% or more patients after chemotherapy
compared to surveillance (Figure 1). We do not have direct data
comparing fertility rates of our patients with normal controls, but
in a study of Norwegian registry data (Fossa and Kravdal, 2000)
fertility was approximately 30% lower in testicular cancer patients
than the normal population. In line with our findings they reported
that lower rates were seen in men who had regional and distant
disease (who presumably had more intensive treatment) (fertility
rate 0.49 (CI 0.36–0.64) compared to 1.0 for normal population)
rather than patients with local disease (0.85 CI 0.67–1.06).
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ing for testicular dysfunction should be a routine part of testicular
cancer follow-up. However, careful thought will need to be given to
the issue as to how one manages any detected hypogonadism.
Hormone supplementation is indicated for the symptomatic
patient with obvious potency problems. The correct management
approach for the ‘asymptomatic’ man with reasonable sexual
activity is more difficult. Testosterone can be replaced by a
number of routes (e.g. patches, gels, implanted pellets), but still the
most common are by intramuscular injections, which when
commenced are likely to be lifelong. Data from other sources
have suggested that hypogonadism is associated with the devel-
opment of osteoporosis and other health effects. Our data have
highlighted the, perhaps more subtle, effects of hypogonadism,
which affects cardiac risk factors such as BMI and blood pressure
and the range of quality of life effects. It is likely that decisions on
this will have to be individualised after careful discussion of the
issues, but suggests that replacement therapy needs to be
considered for this patient group.
In summary, we have found that hormonal dysfunction
is frequent after the diagnosis of testicular cancer and treatment
can have an additional detrimental effect. This can have a
significant impact on the quality of life and contribute to other
health problems. Most patients, however, remain fertile though
this can be affected by their treatment. Screening for hormonal
problems should be considered as a routine part of patient
management.
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